# The role of gene-environment interactions in endocrine-sensitive life stages for shaping mental health: focus on the RE-MEND project

## TL;DR

This paper discusses how gene-environment interactions during key life stages affect mental health and introduces the RE-MEND project to study these factors for better diagnosis and treatment.

## Contribution

The paper introduces RE-MEND, an interdisciplinary project focusing on endocrine-sensitive life stages to uncover mental health risk and resilience factors.

## Key findings

- RE-MEND integrates multi-omics and clinical data to identify mental health risk factors.
- The project aims to develop biomarkers for disease progression and treatment response.
- It seeks to discover new drug targets through repurposing strategies.

## Abstract

The number of people seeking help for mental illness is increasing across all ages, creating a major burden for individuals, families, and the society. While personalized medicine is advancing in other fields, diagnosis and treatment of mental disorders remain largely symptom-based and fail to capture individual, sex, and gender differences in risk, manifestation, and treatment response. Early signs of illness often go unnoticed due to the lack of monitoring tools, and stigma continues to hinder prevention and care. In some phases of life, an individual’s susceptibility to mental illness is heightened and may be influenced by changes in endocrine signalling. To address these challenges, the research project Building REsilience against MEntal illness during ENDocrine-sensitive life stages (RE-MEND) has implemented an interdisciplinary approach focusing on four critical endocrine-sensitive life stages: prenatal, puberty, peripartum, and older age. The project integrates longitudinal population-based cohorts with experimental and clinical studies to identify genetic, environmental, and endocrine factors shaping susceptibility and resilience to mental illness. Multi-omics data (genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics, and adductomics) will be combined with neurobiological, clinical, and behavioural measures, analysed using advanced biostatistics and machine learning. RE-MEND seeks to i) identify risk and resilience factors affecting mental health; ii) deliver biomarker panels for susceptibility, disease progression, and treatment response across sensitive life stages; iii) discover novel drug targets through repurposing strategies, and iv) promote mental health literacy and reduce stigma. The integration of biological research with communication science is anticipated to result in translatable findings, supporting earlier intervention and more effective care.